SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()

Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC. The clinical benefit of sorafenib is offset by the acquisition of sorafenib resistance. Understanding of the molecular mechanism of STAT3...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Jung-Chen, Tseng, Ping-Hui, Wu, Szu-Hsien, Hsu, Cheng-Yi, Tai, Wei-Tien, Li, Yong-Shi, Chen, I-Ting, Liu, Chun-Yu, Chen, Kuen-Feng, Shiau, Chung-Wai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198826/
https://www.ncbi.nlm.nih.gov/pubmed/25047655
http://dx.doi.org/10.1016/j.neo.2014.06.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198826/
https://www.ncbi.nlm.nih.gov/pubmed/25047655
http://dx.doi.org/10.1016/j.neo.2014.06.005

Ejemplares similares